Kariko, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833–1840 (2008).
Google Scholar
Kormann, M. S. et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol. 29, 154–157 (2011).
Google Scholar
Anderson, B. R. et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 38, 5884–5892 (2010).
Google Scholar
Kariko, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165–175 (2005).
Google Scholar
Minnaert, A. K. et al. Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: getting the message across. Adv. Drug Deliv. Rev. 176, 113900 (2021).
Google Scholar
Geall, A. J., Kis, Z. & Ulmer, J. B. Vaccines on demand, part II: future reality. Expert Opin. Drug Discov. 18, 119–127 (2023).
Google Scholar
Bloom, K., van den Berg, F. & Arbuthnot, P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 28, 117–129 (2021).
Google Scholar
Trougakos, I. P. et al. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends Mol. Med. 28, 542–554 (2022).
Google Scholar
Ndeupen, S. et al. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24, 103479 (2021).
Google Scholar
Ju, Y. et al. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines. Nat. Rev. Immunol. 23, 135–136 (2023).
Google Scholar
Low, J. G. et al. A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine. NPJ Vaccines 7, 161 (2022).
Google Scholar
Akahata, W. et al. Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: a randomized, observer-blind phase 1 study. Cell Rep. Med. 4, 101134 (2023).
Google Scholar
Zhong, Z. et al. Corticosteroids and cellulose purification improve, respectively, the in vivo translation and vaccination efficacy of sa-mRNAs. Mol. Ther. 29, 1370–1381 (2021).
Google Scholar
Pepini, T. et al. Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J. Immunol. 198, 4012–4024 (2017).
Google Scholar
Huysmans, H. et al. Expression kinetics and innate immune response after electroporation and LNP-mediated delivery of a self-amplifying mRNA in the skin. Mol. Ther. Nucleic Acids 17, 867–878 (2019).
Google Scholar
Li, Y. et al. In vitro evolution of enhanced RNA replicons for immunotherapy. Sci. Rep. 9, 6932 (2019).
Google Scholar
Blakney, A. K. et al. Innate inhibiting proteins enhance expression and immunogenicity of self-amplifying RNA. Mol. Ther. 29, 1174–1185 (2021).
Google Scholar
Kimura, T. et al. A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation. Mol. Ther. 31, 2360–2375 (2023).
Google Scholar
Kairuz, D., Samudh, N., Ely, A., Arbuthnot, P. & Bloom, K. Advancing mRNA technologies for therapies and vaccines: an African context. Front. Immunol. 13, 1018961 (2022).
Google Scholar
Voigt, E. A. et al. A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability. NPJ Vaccines 7, 136 (2022).
Google Scholar
Beissert, T. et al. A trans-amplifying RNA vaccine strategy for induction of potent protective immunity. Mol. Ther. 28, 119–128 (2020).
Google Scholar
Geall, A., Hekele, A. & Mandl, C. RNA containing modified nucleotides and use thereof in vaccines. WIPO publication no. WO2011/005799A3 (2010); https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2011005799
Erasmus, J. H. et al. Intramuscular delivery of replicon RNA encoding ZIKV-117 human monoclonal antibody protects against Zika virus infection. Mol. Ther. Methods Clin. Dev. 18, 402–414 (2020).
Google Scholar
Pollock, K. M. et al. Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. EClinicalMedicine 44, 101262 (2022).
Google Scholar
Blakney, A. K. et al. Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA. J. Control. Release 304, 65–74 (2019).
Google Scholar
Papukashvili, D. et al. Self-amplifying RNA approach for protein replacement therapy. Int. J. Mol. Sci. 23, 12884 (2022).
Google Scholar
Kairuz, D., Samudh, N., Ely, A., Arbuthnot, P. & Bloom, K. Production, characterization, and assessment of permanently cationic and ionizable lipid nanoparticles for use in the delivery of self-amplifying RNA vaccines. Pharmaceutics 15, 1173 (2023).
Google Scholar
Deering, R. P., Kommareddy, S., Ulmer, J. B., Brito, L. A. & Geall, A. J. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin. Drug Deliv. 11, 885–899 (2014).
Google Scholar
Kariko, K., Muramatsu, H., Ludwig, J. & Weissman, D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 39, e142 (2011).
Google Scholar
Baiersdorfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26–35 (2019).
Google Scholar
de Alwis, R. et al. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. Mol. Ther. 29, 1970–1983 (2021).
Google Scholar
Dinnon, K. H. 3rd et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 586, 560–566 (2020).
Google Scholar
CSL. Japan’s Ministry of Health, Labour and Welfare approves CSL and Arcturus Therapeutics’ ARCT-154, the first self-amplifying mRNA vaccine approved for COVID in adults. https://newsroom.csl.com/2023-11-28-Japans-Ministry-of-Health,-Labour-and-Welfare-Approves-CSL-and-Arcturus-Therapeutics-ARCT-154,-the-first-Self-Amplifying-mRNA-vaccine-approved-for-COVID-in-adults (27 November 2023).
Dolgin, E. Self-copying RNA vaccine wins first full approval: what’s next? Nature 624, 236–237 (2023).
Google Scholar
Zhong, Z. et al. Immunogenicity and protection efficacy of a naked self-replicating mRNA-based Zika virus vaccine. Vaccines 7, 96 (2019).
Google Scholar
Kurhade, C. et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat. Med. 29, 344–347 (2023).
Google Scholar
Miller, J. et al. Substantial neutralization escape by SARS-CoV-2 Omicron variants BQ.1.1 and XBB.1. N. Engl. J. Med. 388, 662–664 (2023).
Google Scholar
Arora, P. et al. Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage. Lancet Infect. Dis. 23, 147–148 (2023).
Google Scholar
Hachmann, N. P., Miller, J., Collier, A. Y. & Barouch, D. H. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.4.6. N. Engl. J. Med. 387, 1904–1906 (2022).
Google Scholar
Andrews, N. et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532–1546 (2022).
Google Scholar
Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654–656 (2022).
Google Scholar
Gao, Y. et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat. Med. 28, 472–476 (2022).
Google Scholar
GeurtsvanKessel, C. H. et al. Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. Sci. Immunol. 7, eabo2202 (2022).
Google Scholar
Addetia, A. et al. Neutralization, effector function and immune imprinting of Omicron variants. Nature 621, 592–601 (2023).
Google Scholar
Keeton, R. et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature 603, 488–492 (2022).
Google Scholar
Kaplonek, P. et al. mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. Immunity 55, 355–365.e4 (2022).
Google Scholar
Aboshi, M. et al. Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine. iScience 27, 108964 (2024).
Google Scholar
Komori, M. et al. Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine. Preprint at bioRxiv https://doi.org/10.1101/2023.11.01.565056 (2023).
Chen, C. K. et al. Structured elements drive extensive circular RNA translation. Mol. Cell 81, 4300–4318.e13 (2021).
Google Scholar
Chen, R. et al. Engineering circular RNA for enhanced protein production. Nat. Biotechnol. 41, 262–272 (2023).
Google Scholar
Kameda, S., Ohno, H. & Saito, H. Synthetic circular RNA switches and circuits that control protein expression in mammalian cells. Nucleic Acids Res. 51, e24 (2023).
Google Scholar
Wesselhoeft, R. A., Kowalski, P. S. & Anderson, D. G. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat. Commun. 9, 2629 (2018).
Google Scholar
Petrakova, O. et al. Noncytopathic replication of Venezuelan equine encephalitis virus and eastern equine encephalitis virus replicons in mammalian cells. J. Virol. 79, 7597–7608 (2005).
Google Scholar
Yoshioka, N. et al. Efficient generation of human iPSCs by a synthetic self-replicative RNA. Cell Stem Cell 13, 246–254 (2013).
Google Scholar
Swart, L. E. et al. A robust post-insertion method for the preparation of targeted siRNA LNPs. Int. J. Pharm. 620, 121741 (2022).
Google Scholar
Kenney, D. J. et al. Humanized mice reveal a macrophage-enriched gene signature defining human lung tissue protection during SARS-CoV-2 infection. Cell Rep. 39, 110714 (2022).
Google Scholar
